Exagen Inc. Reports Fourth Quarter and Full Year 2020 Results
March 16, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year...
BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
March 15, 2021 11:12 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based...
Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
March 15, 2021 08:00 ET
|
Equillium
EQUATE acute graft-versus host disease (aGVHD) study observed rapid response and durability through day 85 EQUATE aGVHD study reported a clinically meaningful reduction in corticosteroid...
Ronald L. Besser announces the publication of ‘The Origins of AIDS and Autism’
March 03, 2021 00:00 ET
|
Archway Publishing
YORK, Pa., March 03, 2021 (GLOBE NEWSWIRE) -- Recent release “The Origins of AIDS and Autism” (published by Archway Publishing) is a collaboration between the Life Laboratory of Spirit and author...
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 16, 2021
March 02, 2021 08:00 ET
|
Exagen Inc.
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, will release financial results for the quarter and year ended December 31, 2020 after the...
Exagen Inc. to Participate in the Cowen 41st Annual Health Care Conference
February 22, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the Cowen 41st Annual Health Care Conference which...
Equillium to Present at the SVB Leerink 10th Annual Global Healthcare Conference
February 18, 2021 08:00 ET
|
Equillium
LA JOLLA, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience
February 12, 2021 15:00 ET
|
Equillium
Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial reduction in baseline corticosteroid use Dose-dependent reduction of CD6 expression on CD4+ and CD8+ T cells is...
Equillium Announces the Appointment of Katherine Xu to the Board of Directors
February 09, 2021 08:00 ET
|
Equillium
LA JOLLA, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Exagen Inc. To Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 03, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the BTIG MedTech, Digital Health, Life Science &...